1. Home
  2. PULM vs LRE Comparison

PULM vs LRE Comparison

Compare PULM & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PULM
  • LRE
  • Stock Information
  • Founded
  • PULM 2003
  • LRE 2001
  • Country
  • PULM United States
  • LRE Japan
  • Employees
  • PULM N/A
  • LRE N/A
  • Industry
  • PULM Biotechnology: Pharmaceutical Preparations
  • LRE
  • Sector
  • PULM Health Care
  • LRE
  • Exchange
  • PULM Nasdaq
  • LRE Nasdaq
  • Market Cap
  • PULM 18.3M
  • LRE 20.5M
  • IPO Year
  • PULM N/A
  • LRE 2023
  • Fundamental
  • Price
  • PULM $4.84
  • LRE $1.19
  • Analyst Decision
  • PULM
  • LRE
  • Analyst Count
  • PULM 0
  • LRE 0
  • Target Price
  • PULM N/A
  • LRE N/A
  • AVG Volume (30 Days)
  • PULM 4.3K
  • LRE 74.5K
  • Earning Date
  • PULM 10-16-2025
  • LRE 01-01-0001
  • Dividend Yield
  • PULM N/A
  • LRE N/A
  • EPS Growth
  • PULM N/A
  • LRE N/A
  • EPS
  • PULM N/A
  • LRE N/A
  • Revenue
  • PULM $3,000.00
  • LRE $110,330,328.00
  • Revenue This Year
  • PULM N/A
  • LRE N/A
  • Revenue Next Year
  • PULM $134.88
  • LRE N/A
  • P/E Ratio
  • PULM N/A
  • LRE N/A
  • Revenue Growth
  • PULM N/A
  • LRE 3.92
  • 52 Week Low
  • PULM $4.26
  • LRE $1.00
  • 52 Week High
  • PULM $10.40
  • LRE $2.97
  • Technical
  • Relative Strength Index (RSI)
  • PULM 47.70
  • LRE 41.75
  • Support Level
  • PULM $4.26
  • LRE $1.17
  • Resistance Level
  • PULM $4.85
  • LRE $1.34
  • Average True Range (ATR)
  • PULM 0.24
  • LRE 0.14
  • MACD
  • PULM -0.02
  • LRE -0.03
  • Stochastic Oscillator
  • PULM 61.11
  • LRE 10.61

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

Share on Social Networks: